Literature DB >> 22659997

Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

A Gurevich1, V Guller, Y N Berner, S Tal.   

Abstract

Atypical antipsychotics seem to be preferable than conventional agents in treating psychological symptoms of dementia (BPSD), because they have substantially lower risks of extrapyramidal neurological effects with lower reported rates of parkinsonism and tardive dyskinesia. However, in the course of time, with the increase in their use, more and more side effects have been reported. The benefits and risks of antipsychotic treatment should be carefully evaluated according to the co-morbidity and the severity of the psychological and behavioral symptoms and their impact on the individual elderly patient. It is recommended to keep those medications in the lower range of therapeutic doses. Due to the complexity of the individual patient, no guidelines have been yet established. Therefore, clinical judgment should be used in applying the dose and the type of those drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659997     DOI: 10.1007/s12603-012-0057-5

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  51 in total

1.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.

Authors:  I R Katz; D V Jeste; J E Mintzer; C Clyde; J Napolitano; M Brecher
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

2.  Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.

Authors:  Rosa Liperoti; Giovanni Gambassi; Kate L Lapane; Claire Chiang; Claudio Pedone; Vincent Mor; Roberto Bernabei
Journal:  Arch Intern Med       Date:  2005-03-28

Review 3.  Hyperglycemia and antipsychotic medications.

Authors:  D W Haupt; J W Newcomer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 4.  Novel versus conventional antipsychotic drugs.

Authors:  R C Love
Journal:  Pharmacotherapy       Date:  1996 Jan-Feb       Impact factor: 4.705

Review 5.  Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.

Authors:  Clive Ballard; Byron Creese; Anne Corbett; Dag Aarsland
Journal:  Expert Opin Drug Saf       Date:  2010-08-05       Impact factor: 4.250

Review 6.  Dyslipidemia and atypical antipsychotic drugs.

Authors:  Daniel E Casey
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 7.  Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?

Authors:  Gianluca Trifirò; Edoardo Spina; Giovanni Gambassi
Journal:  Pharmacol Res       Date:  2008-10-08       Impact factor: 7.658

8.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

9.  Use of atypical antipsychotic drugs in patients with dementia.

Authors:  Charles D Motsinger; Gregory A Perron; Timothy J Lacy
Journal:  Am Fam Physician       Date:  2003-06-01       Impact factor: 3.292

10.  Antipsychotic drug use and mortality in older adults with dementia.

Authors:  Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon
Journal:  Ann Intern Med       Date:  2007-06-05       Impact factor: 25.391

View more
  3 in total

1.  Nonlinear parameters of surface EMG in schizophrenia patients depend on kind of antipsychotic therapy.

Authors:  Alexander Yu Meigal; German G Miroshnichenko; Anna P Kuzmina; Saara M Rissanen; Stefanos D Georgiadis; Pasi A Karjalainen
Journal:  Front Physiol       Date:  2015-07-10       Impact factor: 4.566

2.  Epigenetic Alterations Impact on Antipsychotic Treatment in Elderly Patients.

Authors:  Bryan M McClarty; Daniel W Fisher; Hongxin Dong
Journal:  Curr Treat Options Psychiatry       Date:  2018-01-15

3.  Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.

Authors:  Irina Vasilyeva; Robert G Biscontri; Murray W Enns; Colleen J Metge; Silvia Alessi-Severini
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.